D-dimer Assay for Exclusion of Pulmonary Embolism First to Meet Advanced Standards
By LabMedica International staff writers Posted on 01 Oct 2014 |
Image: The rapid, automated, highly sensitive “STA-Liatest D-Di” – the first D-dimer assay for exclusion of pulmonary embolism to meet the FDA’s approval requirements now based on the new, higher standards established by the Clinical Laboratory Standards Institute (Photo courtesy of Diagnostica Stago).
For the first time a D-dimer assay for exclusion of pulmonary embolism (PE) meets the US Food and Drug Administration (FDA)’s approval requirements now based on the new and more restrictive standards established by the Clinical Laboratory Standards Institute (CLSI, H59-A).
Diagnostica Stago, Inc. (Parsippany, NJ, USA), the US subsidiary of Diagnostica Stago, S.A.S. (Asnières sur Seine, France), a leader in development and manufacture of hemostasis products for clinical research and routine analysis, received the FDA clearance for the reagent “STA-Liatest D-Di” for the exclusion of PE in patients with low or moderate risk, presenting at an emergency unit. Stago’s rapid, automated, and highly sensitive D-dimer assay is the first to comply with the higher standards.
In order to comply with the new CLSI guidelines, Stago performed a 2-year, international, prospective study, similar to clinical studies performed in the pharmaceutical field—9 sites, 5 countries, more than 1,100 patients, including evaluation of clinical pretest probability, imaging, and 3 months of follow-up—a first in the field of hemostasis diagnostics. As its coordinator, Prof. Gilles Pernod of Grenoble University Hospital (France) pointed out: “As well as providing the results required to validate this test for the exclusion of PE, this study brought to light a significant evolution of clinical practices and shifts in prevalence. In fact, these results will be presented in some interesting upcoming publications.”
This study also confirmed the excellent diagnostic performance of the STA-Liatest D-Di assay, with a very high negative predictive value (NPV) for the exclusion of PE, far exceeding FDA requirements (>99.7% versus 97%), and excellent sensitivity (>97% versus 95%). “STA-Liatest D-Di is the first D-Di assay to report comprehensive study data that focuses on US-specific care patterns in the package insert. Increases in FDA stringency raises the bar for demonstration of clinical utility and patient safety. Stago is proud for STA-Liatest D-Di to lead the way once again and set the standard for D-dimer assays,” said Stephane Zamia, PhD, CEO of Diagnostica Stago, Inc.
The second part of this international clinical study, concerning deep vein thrombosis (DVT), is underway and is due to be completed in the next few months, with the hope that it will provide the clinical science community with as much relevant data as the first.
Related Links:
Diagnostica Stago (US)
Diagnostica Stago
Diagnostica Stago, Inc. (Parsippany, NJ, USA), the US subsidiary of Diagnostica Stago, S.A.S. (Asnières sur Seine, France), a leader in development and manufacture of hemostasis products for clinical research and routine analysis, received the FDA clearance for the reagent “STA-Liatest D-Di” for the exclusion of PE in patients with low or moderate risk, presenting at an emergency unit. Stago’s rapid, automated, and highly sensitive D-dimer assay is the first to comply with the higher standards.
In order to comply with the new CLSI guidelines, Stago performed a 2-year, international, prospective study, similar to clinical studies performed in the pharmaceutical field—9 sites, 5 countries, more than 1,100 patients, including evaluation of clinical pretest probability, imaging, and 3 months of follow-up—a first in the field of hemostasis diagnostics. As its coordinator, Prof. Gilles Pernod of Grenoble University Hospital (France) pointed out: “As well as providing the results required to validate this test for the exclusion of PE, this study brought to light a significant evolution of clinical practices and shifts in prevalence. In fact, these results will be presented in some interesting upcoming publications.”
This study also confirmed the excellent diagnostic performance of the STA-Liatest D-Di assay, with a very high negative predictive value (NPV) for the exclusion of PE, far exceeding FDA requirements (>99.7% versus 97%), and excellent sensitivity (>97% versus 95%). “STA-Liatest D-Di is the first D-Di assay to report comprehensive study data that focuses on US-specific care patterns in the package insert. Increases in FDA stringency raises the bar for demonstration of clinical utility and patient safety. Stago is proud for STA-Liatest D-Di to lead the way once again and set the standard for D-dimer assays,” said Stephane Zamia, PhD, CEO of Diagnostica Stago, Inc.
The second part of this international clinical study, concerning deep vein thrombosis (DVT), is underway and is due to be completed in the next few months, with the hope that it will provide the clinical science community with as much relevant data as the first.
Related Links:
Diagnostica Stago (US)
Diagnostica Stago
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data